RE:RE:KuatolivesIt's not really a takeover so much as a merger with another specialty pharma to build scale, and more efficiently access capital ahead of the next steps. TRX shareholders will hold about 40% of the upside of the new company giving account to the warrants and options and before the significant financing. This greatly enhances the opportunity set before the company and puts in place significant capital for the next deals. It also provides scale to realize on Yosprala which is nearing launch, etc.